Media Summary: Axel Grothey, MD, Professor of Oncology and Consultant in the Division of Medical Oncology in the Department of Oncology, ... In this segment, panelists discuss the role of For more resources and information regarding anticancer targeted therapies:
Why Has Everything Beyond Bevacizumab - Detailed Analysis & Overview
Axel Grothey, MD, Professor of Oncology and Consultant in the Division of Medical Oncology in the Department of Oncology, ... In this segment, panelists discuss the role of For more resources and information regarding anticancer targeted therapies: Robert L. Coleman, MD, reviews the approval of In this webinar the Ovacome team are joined by Professor Gordon Jayson BM, BA, Bch, FRCP, PhD, Professor of Medical ... Adam Brufsky, MD, PhD, professor of medicine, associate chief of hematology-oncology, and co-director of the Comprehensive ...
Paul Helft, MD, discusses the rationale for continuing Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent Alberto Farolfi, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy, gives an overview of ...
